Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy

被引：28
|
作者：
Tan, AR [1 ]
Swain, SM [1 ]
机构：
[1] NCI, Canc Therapeut Branch, Canc Res Ctr, Bethesda, MD 20899 USA
来源：
SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 03期
关键词：
D O I：
10.1053/sonc.2002.34059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：77 / 85
页数：9
相关论文
共 50 条
  • [21] Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model
    Mi, Guiyun
    Gao, Yunyun
    Liu, Shuai
    Ye, Enmao
    Li, Yanyan
    Jin, Xiao
    Yang, Hongju
    Yang, Zheng
    CELL CYCLE, 2016, 15 (20) : 2780 - 2791
  • [22] Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
    Migliaccio, Ilenia
    Di Leo, Angelo
    Malorni, Luca
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (06) : 568 - 575
  • [23] Flavopiridol, a cyclin-dependent kinase inhibitor, represses HIV-1 transcription in macrophages
    Caldwell, RL
    Shepherd, VL
    FASEB JOURNAL, 2003, 17 (05): : A1039 - A1039
  • [24] Cyclin-Dependent Kinase Modulators and Cancer Therapy
    Gallorini, Marialucia
    Cataldi, Amelia
    di Giacomo, Viviana
    BIODRUGS, 2012, 26 (06) : 377 - 391
  • [25] Cyclin-Dependent Kinase Modulators and Cancer Therapy
    Marialucia Gallorini
    Amelia Cataldi
    Viviana di Giacomo
    BioDrugs, 2012, 26 (6) : 377 - 391
  • [26] Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
    Li BinBin
    Wang Bo
    Zhu ChengMing
    Tang Di
    Pang Jun
    Zhao Jing
    Sun ChunHui
    Qiu MiaoJuan
    Qian ZhiRong
    慢性疾病与转化医学（英文）, 2019, 5 (03) : 155 - 169
  • [27] The cyclin-dependent kinase inhibitor flavopiridol potentiates γ-irradiation-induced apoptosis in colon and gastric cancer cells
    Jung, C
    Motwani, M
    Kortmansky, J
    Sirotnak, FM
    She, YH
    Gonen, M
    Haimovitz-Friedman, A
    Schwartz, GK
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6052 - 6061
  • [28] Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol
    de Azevedo, WF
    Canduri, F
    da Silveira, NJF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (01) : 566 - 571
  • [29] Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flavopiridol: Modulation of cdk targets in clinical samples
    Di Vizio, D
    O'Connell, FP
    Bhattacharya, N
    Shapiro, GI
    Loda, M
    MODERN PATHOLOGY, 2005, 18 : 297A - 297A
  • [30] The cyclin-dependent kinase inhibitor flavopiridol inhibits glycogen phosphorylase and affects glucose metabolism.
    Kaiser, AU
    Nishi, K
    Walsh, DA
    Gorin, FA
    Bradbury, EM
    Schnier, JB
    CLINICAL CANCER RESEARCH, 1999, 5 : 3754S - 3754S
12345